Ken Griffin Medical Devices

Citadel Advisors LLC

$559 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
PACB Pacific Biosciences Of California, Inc.	$326M	$660,000 0.0% of portfolio	360,981	Q4 2024 Added 1,640,722.75%
SRDX Surmodics Inc	$460M	$608,000 0.0% of portfolio	15,373	Q4 2024 Added 463.53%
SMLR Semler Scientific, Inc.	$292M	$601,000 0.0% of portfolio	11,131	Q4 2024 Reduced 46.63%
ZIMV Zim Vie Inc.	$346M	$577,000 0.0% of portfolio	41,097	Q4 2024 Reduced 94.6%
AVNS Avanos Medical, Inc.	$700M	$532,000 0.0% of portfolio	33,418	Q4 2024 Reduced 66.22%
ARAY Accuray Inc	$188M	$489,000 0.0% of portfolio	247,296	Q4 2024 Reduced 30.0%
MASS 908 Devices Inc.	$70.8M	$433,000 0.0% of portfolio	197,183	Q4 2024 Reduced 9.19%
NPCE Neuro Pace Inc	$322M	$432,000 0.0% of portfolio	38,607	Q4 2024 Added 134.25%
QIPT Quipt Home Medical Corp.	$93.5M	$402,000 0.0% of portfolio	131,970	Q4 2024 Reduced 20.41%
CLPT Clear Point Neuro, Inc.	$356M	$387,000 0.0% of portfolio	25,178	Q4 2024 Reduced 70.69%
VMD Viemed Healthcare, Inc.	$300M	$373,000 0.0% of portfolio	46,549	Q4 2024 Added 32.39%
PROF Profound Medical Corp.	$144M	$346,000 0.0% of portfolio	46,091	Q4 2024 Added 71.06%
TCMD Tactile Systems Technology Inc	$288M	$340,000 0.0% of portfolio	19,896	Q4 2024 Added 1,822.32%
NVNO En V Veno Medical Corp	$30.1M	$313,000 0.0% of portfolio	106,316	Q4 2024 Added 10,478.71%
BWAY Brainsway Ltd.	$158M	$300,000 0.0% of portfolio	32,133	Q4 2024 Reduced 39.55%
IRMD Iradimed Corp	$677M	$291,000 0.0% of portfolio	5,304	Q4 2024 New
BIO Bio Rad Laboratories, Inc.	$6.53B	$283,000 0.0% of portfolio	864	Q4 2024 Reduced 95.78%
RCEL Avita Medical, Inc.	$228M	$208,000 0.0% of portfolio	16,319	Q4 2024 Reduced 47.16%
BVS Bioventus Inc.	$625M	$175,000 0.0% of portfolio	16,730	Q4 2024 Reduced 93.78%
TELA Tela Bio, Inc.	$46.9M	$170,000 0.0% of portfolio	56,510	Q4 2024 Added 293.47%
EDAP Edap Tms Sa	$92.5M	$144,000 0.0% of portfolio	65,242	Q4 2024 Added 78.44%
FNA Paragon 28, Inc.	$1B	$142,000 0.0% of portfolio	13,770	Q4 2024 Reduced 72.33%
IRIX Iridex Corp	$22.1M	$115,000 0.0% of portfolio	67,653	Q4 2024 Added 34.56%
APYX Apyx Medical Corp	$50.1M	$104,000 0.0% of portfolio	66,355	Q4 2024 Added 427.76%
LNSR Lensar, Inc.	$143M	$94,000 0.0% of portfolio	10,700	Q4 2024 Added 169.73%
LUCD Lucid Diagnostics Inc.	$57.1M	$94,000 0.0% of portfolio	119,887	Q4 2024 New
IINN Inspira Technologies Oxy B.H.N. LTD	$9.97M	$90,000 0.0% of portfolio	86,763	Q4 2024 Added 422.54%
MODD Modular Medical, Inc.	$9.28M	$88,000 0.0% of portfolio	64,495	Q4 2024 New
ICAD Icad Inc	$61.1M	$79,000 0.0% of portfolio	43,223	Q4 2024 Reduced 69.26%
AXGN Axogen, Inc.	$846M	$73,000 0.0% of portfolio	4,437	Q4 2024 Reduced 47.45%
CUTR Cutera Inc	$7.05M	$67,000 0.0% of portfolio	193,998	Q4 2024 Added 72.32%
NMTC Neuroone Medical Technologies Corp	$18.2M	$67,000 0.0% of portfolio	81,802	Q4 2024 New
RPID Rapid Micro Biosystems, Inc.	$111M	$64,000 0.0% of portfolio	72,024	Q4 2024 New
ELMD Electromed, Inc.	$230M	$45,000 0.0% of portfolio	1,530	Q4 2024 Reduced 91.93%
AZYO Aziyo Biologics, Inc.	$13.5M	$32,000 0.0% of portfolio	22,431	Q4 2024 New
CODX Co Diagnostics, Inc.	$16.9M	$12,000 0.0% of portfolio	16,466	Q4 2024 Reduced 35.23%
HYPR Hyperfine, Inc.	$53.9M	$9,000 0.0% of portfolio	10,346	Q4 2024 Reduced 18.29%
OM Outset Medical, Inc.	$35M	$3,000 0.0% of portfolio	2,922	Q3 2024 Reduced 99.0%

Shares Options

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Ken Griffin's portfolio

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account